Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
SX60 Degrees Pharmaceuticals, Inc. logo

60 Degrees Pharmaceuticals, Inc. (SXTP)

NASDAQ Capital Market · Currency in USD
$0.87 ▼ -0.01 (-0.66%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.89 ▲ +0.01 (+1.71%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$0.88
Open
$0.82
Day's Range
$0.82 – $0.93
52 Week Range
$0.81 – $8.62
Volume
12,765
Avg. Volume
115,321
Market Cap
$3.06M
Beta (5Y Monthly)
2.40
PE Ratio (TTM)
--
EPS (TTM)
-$3.06
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: 60 Degrees Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
3
CEO
Geoffrey Stuart Dow

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.61 · Revenue est. $270.00K
DateEst.Actual
Aug 14, 2026-$0.74-$0.90Miss
May 15, 2026-$0.76-$1.28Miss
Mar 26, 2026-$2.28-$1.69Beat
Nov 13, 2025-$1.84-$2.64Miss
Aug 12, 2025-$4.96-$5.00Miss
May 15, 2025-$5.24-$6.24Miss

Analyst view

Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on SXTP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.